Shield Post-Approval Study Protocol (NCT06880055)
🩺 Plain-English Summary (8th-Grade Level)
The Shield post-approval study (PAS) is a prospective, longitudinal study supplemented with Real World Evidence (RWE) to evaluate the longitudinal performance of Shield in an average risk population at a second round of testing for individuals between the ages of 45 and 81 at average risk of CRC using colonoscopy as the reference method.
Who can join: Review the eligibility criteria below.
Location: Southeast Valley Gastroenterology Consultants — Chandler, Arizona
Age range: 45 Years to 81 Years
🧪 Interventions in This Study
- Shield Blood Test for colo-rectal cancer Screening (DIAGNOSTIC_TEST)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (69 Sites)
Showing the first 25 of 69 sites.
- Southeast Valley Gastroenterology Consultants — Chandler, Arizona
- Southeast Valley Gastroenterology Consultants — Gilbert, Arizona
- Elite Primary Physicians, Inc. — Anaheim, California
- Alliance Research Institute, LLC — Canoga Park, California
- Paragon Rx Clinical, Inc. — Garden Grove, California
- Amicis Research Center — Granada Hills, California
- Desert Oasis Healthcare Medical Group — Palm Springs, California
- Amicis Research Center — Sherman Oaks, California
- Amicis Research Center — Valencia, California
- Coral Clinics — Winnetka, California
- Digestive Disease Associates — Branford, Connecticut
- Digestive Disease Associates — Branford, Connecticut
- Gastroenterology Consultants of Boca Raton, LLC — Boca Raton, Florida
- Manuel Espinel MD PA — Delray Beach, Florida
- Innova Pharma Research, LLC — Doral, Florida
- Marisela Gonzalez, MD — Miami, Florida
- Research Associates of South Florida, LLC — Miami, Florida
- Florida South Research Phase I-IV, Inc. — Miami, Florida
- Physicians Group of South Florida — North Miami, Florida
- NMC Research — Tampa, Florida
- Digestive Disease Consultants — Bourbonnais, Illinois
- Digestive Disease Consultants — Bourbonnais, Illinois
- Christie Clinic — Champaign, Illinois
- Christie Clinic — Champaign, Illinois
- GI Solutions of Illinois — Chicago, Illinois
📞 Contact the Study Coordinator
Phone: (415) 307-2774
Email: solar@guardanthealth.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Colo-rectal Cancer
- EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer — Buffalo, New York
- Decision Counseling and Follow-up for Shield+ Patients — Philadelphia, Pennsylvania
- Eliminating Barriers to Colorectal Cancer Screening Using Rapid Cycle Testing: A Pilot Study — Boston, Massachusetts
- Colorectal Cancer Screening Outreach — New Haven, Connecticut
- A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE) — Gainesville, Florida
- Evaluation of SINGLE PORT (SP) Robotic Technology in Colorectal Surgery — Sacramento, California
Explore by condition: All Colo-rectal Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.